ViiV Healthcare HIV Medications to be Discontinued as of January 1, 2024
Posted December 16, 2022Announcement: ViiV Healthcare HIV Medications to be Discontinued as of January 1, 2024
Last year, ViiV Healthcare (“ViiV”) released a letter notifying health care providers
that the following products will be discontinued in the United States, and will no longer be distributed by ViiV as of January 1, 2024:
- Lexiva (fosamprenavir) 700 mg Tablets and 50 mg/ml Oral Suspension
- Trizivir (abacavir/lamivudine/zidovudine) 300 mg/150 mg/300 mg Tablets
- Selzentry (maraviroc) 25 mg Tablets and 75 mg Tablets
- Tivicay (dolutegravir) 10 mg Tablets and 25 mg Tablets
- Ziagen (abacavir) 300 mg Tablets
- Combivir (lamivudine/zidovudine) 150 mg/300 mg Tablets
- Epzicom (abacavir/lamivudine) 600 mg/300 mg Tablets
In addition, in the letter ViiV stated it would no longer accept new Patient Assistance Program (PAP) applications for the products listed above after 07/01/22.
For any questions or concerns, please contact the ViiV Healthcare Customer Response Center at 1-877-844-8872.
